Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes
| Autor: | WS Klittich, Cathy Sigler, Gabriel Raggio, Kenneth M. Flegel, Catherine Copley-Merriman, Patricia L. Kavanagh, Judith A. O'Brien, J. Jaime Caro, Lori A. Shomphe |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Blood Glucose Male Pediatrics medicine.medical_specialty Cost effectiveness Cost-Benefit Analysis Population Type 2 diabetes Drug Costs law.invention Cohort Studies Troglitazone Randomized controlled trial law Diabetes mellitus medicine Humans Hypoglycemic Agents Pharmacology (medical) Chromans education Glycemic Aged Randomized Controlled Trials as Topic Pharmacology education.field_of_study business.industry Type 2 Diabetes Mellitus Middle Aged medicine.disease United States Surgery Thiazoles Models Economic Sulfonylurea Compounds Diabetes Mellitus Type 2 Female Thiazolidinediones business medicine.drug |
| Zdroj: | Clinical therapeutics. 22(1) |
| ISSN: | 0149-2918 |
| Popis: | Objective To assess the economic efficiency of adding troglitazone to sulfonylurea therapy to improve glycemic control. Background Despite the high prevalence of type 2 diabetes, existing treatment strategies often fail. New oral agents give a wider segment of the population with type 2 diabetes hope of achieving near-normal blood-glucose levels. Troglitazone, a novel chemical entity, is one promising new agent. Methods We conducted an economic analysis based on glycemic-control data from a randomized clinical trial comparing troglitazone with placebo, each added to glyburide. A patient simulation model was used to translate these data to long-term outcomes associated with diabetes. Patients had poorly controlled type 2 diabetes mellitus despite glyburide therapy. Risk functions of developing and progressing through nephropathy, retinopathy, neuropathy, hypoglycemia, and macrovascular disease were developed from the Diabetes Control and Complications Trial and large epidemiologic studies. Cost estimates were based on data from 5 states, all payor databases, surveys, and literature. The main outcomes of the model were cost-consequences, number of patients developing each type of complication, mean time to development of the complication, cost per life-year gained (LYG), and cost per quality-adjusted life-year. Results The model predicts that for every 1000 patients treated with troglitazone, the improved glycemic control could mean that 95 to 140 fewer patients would experience one of the most severe diabetic complications (eg, blindness, end-stage renal disease, amputation), which may increase life expectancy by 2.0 years. These benefits are obtained at an additional $2100 per LYG (undiscounted). The ratio remains Conclusions The clinical trial demonstrated that troglitazone + glyburide improves glycemic control compared with glyburide alone. Based on these results, the model estimates fewer diabetic complications at a cost well below accepted cost-effective thresholds. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect